![mine](https://robbinsllp.com/wp-content/uploads/2021/07/mine-300x300.jpg)
Investigation of Piedmont Lithium Inc.
Piedmont Lithium Inc. (PLL) Misled Investors Regarding its Timeliness in Obtaining Permits During the relevant period, defendants informed investors of the necessity of obtaining the proper mining permits and
Piedmont Lithium Inc. (PLL) Misled Investors Regarding its Timeliness in Obtaining Permits During the relevant period, defendants informed investors of the necessity of obtaining the proper mining permits and
Activision Blizzard, Inc. (ATVI) Accused of Sexual Harassment Against Female Employees After a two-year investigation, the California Dept. of Fair Employment and Housing filed a lawsuit against the Company alleging
Coinbase Global, Inc. (COIN) Made False and Misleading Statements in its Offering Materials Supporting its IPO Coinbase Global, Inc. (COIN) held its IPO on April 14, 2021, registering for
Stable Road Acquisition Corp. (SRAC) Made Misstatements Regarding its Business Prospects On October 7, 2020, Stable Road and Momentus issued a joint press release announcing that Stable Road had agreed
Akebia Therapeutics, Inc. (AKBA) Failed to Provide Relevant Information to Keryx Shareholders in Advance of the Merger The Registration Statement issued in connection with the December 2018 merger of Keryx
CarLotz, Inc. (LOTZ, LOTZW) Made False and Misleading Statements Regarding its Busines,s Operations, and Prospects CarLotz became a public entity via merger with Acamar Partners Acquisition Corp., a blank
Home Point Capital Inc. (HMPT) Made Misstatements in its IPO Offering Documents Home Point conducted its IPO on January 29, 2021, selling its stock at $13.00 per share for proceeds
Tarena International, Inc. (TEDU) Made Misstatements Regarding its Accounting Practices During the class period, defendants made false and misleading statements and/or failed to disclose that: (1) certain employees were
Frequency Therapeutics, Inc. (FREQ) Misstated the Potential of its Hearing Loss Treatment FX-322 Frequency Therapeutics began its Phase 2a trial for FX-322 in October 2019. The trial results failed
Attorney Advertising. Past results do not guarantee a similar outcome.
5060 Shoreham Pl., Ste. 300 San Diego, CA 92122
Disclaimer | Site Map | Privacy Policy
© 2024 – Robbins LLP
Stock Watch members receive free investment monitoring and notifications.